SCHEMBL19730160

SCHEMBL19730160

Nc1nc(O)cc2[nH]cnc12

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PNP P00491 1/20 0.44
LMNA P02545 2/20 0.42
MEN1 O00255 3/20 0.41
KMT2A Q03164 3/20 0.41
POLB P06746 1/20 0.41
ALDH1A1 P00352 4/20 0.38
MAPT P10636 3/20 0.38
KDM4E B2RXH2 2/20 0.38
APEX1 P27695 1/20 0.38
RECQL P46063 1/20 0.38
BLM P54132 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
PRKCI P41743 1/20 0.36
PRNP P04156 1/20 0.36
HPGD P15428 1/20 0.36
HTT P42858 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
RAD52 P43351 1/20 0.35
PARP1 P09874 1/20 0.35
GDA Q9Y2T3 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4444492 0.80 LMNA (0.44) PNPLMNAMEN1KMT2APOLB
SCHEMBL18398246 0.80 PNP (0.47) PNPLMNAMEN1KMT2APOLB
SCHEMBL19714843 0.78 PNP (0.46) PNPLMNAMEN1KMT2APOLB
SCHEMBL19730144 0.77 PNP (0.44) PNPLMNAMEN1KMT2APOLB
SCHEMBL17253692 0.77 PNP (0.44) PNPLMNAMEN1KMT2APOLB
SCHEMBL19738355 0.73 PNP (0.41) PNPLMNAMEN1KMT2AALDH1A1
SCHEMBL3071563 0.71 PNP (0.46) PNPLMNAMEN1KMT2APOLB
Isoguanine SCHEMBL887740 0.67 PARP1 (0.36) PNPLMNAMEN1KMT2APOLB
SCHEMBL563514 0.65 MMP12 (0.44) PNPLMNAMEN1KMT2APOLB
SCHEMBL28871076 0.65 PNP (0.48) PNPLMNAMEN1KMT2APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170362235-A1 ADENYLYL CYCLASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHOD OF USE THEREOF VASADE BIOSCIENCES, INC. 2017-12-21 US disclosed
US-20170362235-A1 ADENYLYL CYCLASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHOD OF USE THEREOF VASADE BIOSCIENCES, INC. 2017-12-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170362235-A1 ADENYLYL CYCLASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHOD OF USE THEREOF ADCY1, ADCY2, ADCY5 PNP 288/4885LMNA 1207/4885MEN1 3388/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.